Semnur Pharmaceuticals, Inc.

What they do

Semnur is a late-stage clinical specialty pharmaceutical company focused on developing its only product candidate, SP-102. The company was formed through a September 22, 2025 reverse recapitalization between Denali Capital Acquisition Corp. and Legacy Semnur. It currently has no commercial products, no sales and marketing organization, and has not generated any revenue from product sales.

Revenue drivers

• SP-102 (product candidate) — The company's sole product candidate; no regulatory approval, no product revenue, and no commercial sales to date.

Recent performance

The company reported a net loss of $160.4 million for fiscal 2025, compared to a net loss of $4.7 million in 2024, with diluted EPS of -$0.78 for 2025 and -$0.02 for 2024. Operating cash flow was -$5.9 million in 2025, following -$4.9 million in 2024. As of June 30, 2026, cash and equivalents were $39,000, total assets were $1.9 million, total liabilities were $31.6 million, and shareholder equity was -$29.7 million. The company acknowledges substantial doubt about its ability to continue as a going concern.

Strategy

Management's stated direction is to advance the clinical development of SP-102, its only product candidate, toward potential approval and commercialization. The company has not established a sales and marketing organization and acknowledges that doing so will be necessary for commercialization. The strategy also includes managing the capital-intensive clinical development process, although the company's negative cash flows and liquidity position present significant constraints.

Risks

• Going concern risk — Recurring losses, negative cash flows, and substantial cumulative net losses raise substantial doubt about the company's ability to continue as a going concern.
• Single product dependence — The company has only one product candidate, SP-102, and if it fails in clinical development or regulatory approval, the company may not have any viable product.
• No revenue or commercialization capability — The company has never generated product revenue and lacks a sales and marketing organization, which may prevent successful commercialization of SP-102 if approved.
• Liquidity constraints — With only $39,000 in cash and negative shareholder equity of -$29.7 million as of June 30, 2026, the company may be unable to fund ongoing operations without additional financing.

Outlook

Management expects continued losses for the foreseeable future as it advances SP-102 through clinical development. The company faces immediate liquidity challenges, with minimal cash and a need to raise additional capital to continue operations. The 10-K and 10-Q do not provide specific forward-looking milestones or revenue projections, and the company's ability to execute on its strategy depends on its access to financing.